VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
For business and technology leaders, this development is significant because sepsis remains a leading cause of death worldwide, and rapid early detection is critical for improving patient outcomes. The finger-prick prototype could enable testing in settings where traditional lab infrastructure is unavailable, such as rural clinics, ambulances, or even home care. This aligns with the growing trend toward decentralized healthcare and point-of-care diagnostics, which can reduce time to diagnosis and treatment.
Volition is focused on advancing the science of epigenetics and is developing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The potential impact of this breakthrough extends beyond sepsis. The ability to detect nucleosomes from a finger-prick sample could open up applications for other conditions where nucleosome levels are relevant, such as cancer monitoring. The broader addressable market for point-of-care testing is substantial, and Volition’s approach could position it as a key player in the expanding diagnostics market.
For more details, the full press release is available at https://ibn.fm/ioEmu. Further information about Volition can be found on its website at www.Volition.com.
